| [1] |
Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies[J]. Nat Rev Clin Oncol, 2015, 12(6):319-334. DOI: 10.1038/nrclinonc.2015.53.
doi: 10.1038/nrclinonc.2015.53
pmid: 25824606
|
| [2] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. DOI: 10.3322/caac.21590.
doi: 10.3322/caac.v70.1
|
| [3] |
Zhu X, Li F, Liu W, et al. Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: a propensity score-matched analysis of a prospectively collected database[J]. Cancer Manag Res, 2018, 10:1295-1304. DOI: 10.2147/CMAR.S163655.
doi: 10.2147/CMAR
|
| [4] |
Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma[J]. Acta Oncol, 2015, 54(7):979-985. DOI: 10.3109/0284186X.2015.1004367.
doi: 10.3109/0284186X.2015.1004367
pmid: 25734581
|
| [5] |
Tchelebi LT, Lehrer EJ, Trifiletti DM, et al. Conventionally fractio-nated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis[J]. Cancer, 2020, 126(10):2120-2131. DOI: 10.1002/cncr.32756.
doi: 10.1002/cncr.32756
pmid: 32125712
|
| [6] |
Lischalk JW, Burke A, Chew J, et al. Five-fraction stereotactic body radiation therapy (SBRT) and chemotherapy for the local management of metastatic pancreatic cancer[J]. J Gastrointest Cancer, 2018, 49(2):116-123. DOI: 10.1007/s12029-016-9909-2.
doi: 10.1007/s12029-016-9909-2
|
| [7] |
Ren G, Zhu F, Wang YJ, et al. A phase Ⅱ study of oral S-1 with concurrent hypofractionated simultaneous integrated boost radiotherapy for metastatic pancreatic cancer using helical tomotherapy[J]. J Clin Oncol, 2017, 35(15_suppl):e15720. DOI: 10.1200/JCO.2017.35.15_suppl.e15720.
doi: 10.1200/JCO.2017.35.15_suppl.e15720
|
| [8] |
Ren G, Feng Z, Zhu F, et al. A phase Ⅰ trial of high-dose sbrt followed by the gastrointestinal shunt procedure for local pancreatic head and neck carcinoma: to approach a new mode of cooperation of radiotherapy and surgery[J]. Int J Radiat Oncol Biol Phys, 2018, 102(3S):e78. DOI: 10.1016/j.ijrobp.2018.07.431.
|
| [9] |
夏廷毅, 孙庆选, 于涌, 等. 体部γ刀治疗52例胰腺癌的疗效分析[J]. 中华肝胆外科杂志, 2006, 12(2):86-88. DOI: 10.3760/cma.j.issn.1007-8118.2006.02.006.
|
| [10] |
常冬姝, 夏廷毅, 李平, 等. 全身γ刀治疗局限期胰腺癌临床结果分析[J]. 中华放射肿瘤学杂志, 2009, 18(6):470-473. DOI: 10.3760/cma.j.issn.1004-4221.2009.06.470.
|
| [11] |
任刚, 夏廷毅. 胰腺癌放疗剂量模式改变的研究进展[J]. 中华结直肠疾病电子杂志, 2016, 5(2):121-126. DOI: 10.3877/cma.j.issn.2095-3224.2016.02.03.
|
| [12] |
Hanna GG, Murray L, Patel R, et al. UK consensus on normal tissue dose constraints for stereotactic radiotherapy[J]. Clin Oncol, 2018, 30(1):5-14. DOI: 10.1016/j.clon.2017.09.007.
doi: 10.1016/j.clon.2017.09.007
|
| [13] |
吴伟章, 朱夫海, 王勇. Tomotherapy摆位误差修正的精度及其对PTV外放边界的影响[J]. 实用肿瘤杂志, 2016, 31(2):53-56. DOI: 10.13267/j.cnki.syzlzz.2016.02.020.
|
